206 related articles for article (PubMed ID: 29328401)
1. Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer.
Ma L; Wang F; Du C; Zhang Z; Guo H; Xie X; Gao H; Zhuang Y; Kornmann M; Gao H; Tian X; Yang Y
Oncol Rep; 2018 Mar; 39(3):1132-1140. PubMed ID: 29328401
[TBL] [Abstract][Full Text] [Related]
2. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells.
Li H; Wang P; Liu J; Liu W; Wu X; Ding J; Kang J; Li J; Lu J; Pan G
J Clin Lab Anal; 2020 Sep; 34(9):e23369. PubMed ID: 32618397
[TBL] [Abstract][Full Text] [Related]
5. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
8. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
9. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
10. Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.
Xiong Y; Wang J; Zhu H; Liu L; Jiang Y
Oncol Rep; 2018 Mar; 39(3):967-976. PubMed ID: 29328404
[TBL] [Abstract][Full Text] [Related]
11. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
12. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
13. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
Song Y; Zou L; Li J; Shen ZP; Cai YL; Wu XD
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8161-8168. PubMed ID: 30556854
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
[TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNA MEG3 suppresses epithelial‑to‑mesenchymal transition by inhibiting the PSAT1‑dependent GSK‑3β/Snail signaling pathway in esophageal squamous cell carcinoma.
Li MK; Liu LX; Zhang WY; Zhan HL; Chen RP; Feng JL; Wu LF
Oncol Rep; 2020 Nov; 44(5):2130-2142. PubMed ID: 32901893
[TBL] [Abstract][Full Text] [Related]
16. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
You L; Wang H; Yang G; Zhao F; Zhang J; Liu Z; Zhang T; Liang Z; Liu C; Zhao Y
Mol Oncol; 2018 Dec; 12(12):2147-2164. PubMed ID: 30341811
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X
Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
20. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
Wang Z; Jiang J; Qin T; Xiao Y; Han L
J Cell Mol Med; 2019 Apr; 23(4):2678-2688. PubMed ID: 30761741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
